Streetbeat News

Analyst Ratings

SLAB

Keybanc analyst John Vinh has maintained an Overweight rating on Silicon Laboratories (NASDAQ:SLAB), but lowered the price target from $180 to $130.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:51 pm

TENB

Barclays analyst Saket Kalia maintains an Equal-Weight rating on Tenable Holdings (NASDAQ:TENB) but lowers the price target from $47 to $41.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:49 pm

RRX

Keybanc analyst Jeffrey Hammond maintains an Overweight rating on Regal Rexnord (NYSE:RRX) but lowers the price target from $184 to $148.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:49 pm

SMCI

Barclays analyst George Wang maintains an Overweight rating on Super Micro Computer (NASDAQ:SMCI) and raises the price target from $327 to $335.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:48 pm

PCOR

Keybanc analyst Jason Celino maintains an Overweight rating on Procore Technologies (NYSE:PCOR) but has lowered the price target from $85 to $65.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:47 pm

SPWR

Barclays analyst Christine Cho has maintained an Underweight rating on SunPower (NASDAQ:SPWR) and lowered the price target from $6 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:46 pm

SHC

Barclays analyst Luke Sergott has maintained an Overweight rating on Sotera Health (NASDAQ:SHC) but lowered the price target from $20 to $15.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:45 pm

MTRN

Keybanc analyst Philip Gibbs maintains an Overweight rating on Materion (NYSE:MTRN) and raises the price target from $128 to $130.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:45 pm

SKY

Barclays analyst Matthew Bouley maintains an Equal-Weight rating on Skyline Champion (NYSE:SKY) and lowers the price target from $66 to $61.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:43 pm

SRPT

Barclays analyst Gena Wang has maintained an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT) but lowered the price target from $193 to $141.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 3:42 pm